The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
So why are you here then?
We are at the commercial end of proceedings. Your frustration borne over time is irrelevant.
Stop with the petulance, it’s boring!
A growing interest and justification for live surveillance across the board. This test enabled results within 5 hours, our tech enables results within seconds.
It’s coming
Introduce A.I and instant detection at all 500+ sites and that’s £25m in sales strength off the bat. Goes to show the shear scale of potential value that can be created by what Deepverge has given the additional value its product offers.
We are also seeing growing coverage in the U.S. let’s hope GB blows it out of the park because it would appear that the potential market is ready for DVRG.
Hi G, I am on Twitter and GB has been pretty hot on near enough all that I have tweeted in the last several days since my initial investment, except for any reference to the breath test.
These are not concerns, but as part of my research and reading the various forums, I can understand why many have been frustrated with the stagnated share price performance over the last 6 months. However, a majority of what would signify progress has been dependent on outcomes outside of the companies control. Last weeks independent validation of the detection of Sars-cov-2 in wastewater enables both government and businesses alike to accelerate any signing of contracts as part of the immediate need to enhance the detection of this virus.
For me now the clock starts ticking as all communication to date from GB has implied that discussions were/are already underway with the intention/indication that something would materialize in the near future.
Our third quarter could well define what has been stated as a news rich period within the first few weeks of this coming quarter, said to be as exciting as the first 6 months.
We all understand what the implications of GB and team delivering on multiple fronts would mean for all involved, ‘transformational’ is maybe an understatement.
All comms seem to have gone radio silent since that statement referring to the phase III readout as imminent.
I am expecting something to be said on this in the forward looking statement as you would with all divisions of the business.
I would also like the nature of the alternative Chinese deal to be revealed within the statement so to understand the nature of any reformed potential deal.
Thank you for clarifying.
Over the course of the last 3 trading days we have seen 3 particularly large trades which represent approximately 1.5% of the shareholder register. In conjunction with the continued round number trades that have exploited an increase in private investor appetite/volume.
With 15.5% of the register owned by directors and one particular institution which only yesterday reported an unchanged position. It would be fair to assume that the seller has less than 3% of the company or what would be approx 6.5m shares.
With that in mind, to have witnessed the block selling it would be reasonable to conclude that the seller is near to finishing if they haven’t already as they don’t have a position exceeding 3% or it would have been disclosed. Unless we have more than one major seller at the same time which IMO is unlikely, additional news over the next few weeks as reported should see this share price finally breakout.
Its been reported as imminent, but all is quite, I expect that this could drop at any point.
Sounds to me like a Hong Kong listing is on its way as the deal has moved on from a JV to what otherwise sounds like a combined sum of parts for the roll out of this monitoring system through China with additional information/update to coming next week.
Cov-SARS-2 - validation now initiates pressing need for immediate product installation
China Mou - facilitates capacity to meet immediate need as government will not want to see delays to installation once orders are confirmed in order to save face.
Contracts - currently under NDA will roll out for installation of above at a pace that is leveraged through other distribution networks such as EPS group and others.
Newsflow to intensify and drive the volume that gets rid of the weak hands over the proceeding days/weeks/months.
Investment case validated today, just need to sit back and watch it all unravel.
This deal has just added significant value to our JV with China resources and speaks for itself as to why we needed to increase capacity to such an extent with an oem to satisfy demand. Once capacity/JV is addressed we will be able to sign the widely touted NDA’s throughout Europe as disclosed at the G7.
As GB has said before, we go from 100’s of units to ten of thousands of units and EPS for starters allow us to leverage distribution channels through their partners.
Huge and very welcome news with Q3 to really transform the company, yet again
Already confirmed in a previous RNS that results will be released to market on Monday, expecting forward guidance for the remainder of 2021 and perhaps a revision to the projected £10m revenue.
These are not every day trades, we only need to look to the trading history to see that this type of transaction is infrequent at best and more importantly may signify the end of an exit for a particular shareholder.
Tomorrow might mark the beginning of a recovery as FOMO approaches through to the end of the month in anticipation of next weeks news.
- Approx 17% of total market cap backed by cash.
- China Resources is a game changing JV said to be non dilutive, increases capacity to meet ‘country’ contract demand in 18 month installed rollout from September.
- Question is, will the MHRA phase three breath test also validate the Covid waste water pathogen, as they are one of the same I would say it does. Therefore it becomes the enabler to contracts on both fronts.
My best guess
N - It certainly has a lot going for it, the chart TA looks ripe to rip.
I continue to read and learn, it would appear to me that the current shareholder register is frustrated by pace of disclosed progress. For me the institutions will arrive in significant numbers if all falls into place, and certainly if revenue for 2021 increases at a pace anywhere near to what some have suggested on here. All seems up for grabs.
It’s interesting that he made reference in June 2020 to a business model that he had used in a previous company of his that was able to increase turnover from 5/35m within two years by actively partnering with others which in turn reduced capex and took advantage of other companies distribution channels.
You can see the volume/capacity from the China Resources deal that would take the Wastewater monitoring arm to another level and allow for the widely touted deals in Europe as part of a wider expansion via an OEM. It’s first major deal would then prove to others it’s immediate value and would facilitate a rapid growth in deals.
It has taken me a while to get my head around what appears to be the commercialization roadmap, but it’s all their to be pieced together.
If this turns out to be anything like what I think it could, today’s market cap is simply ludicrous and presents a unique proposition.
Is anyone expecting an upwards revision to 2021 £10m revenue guidance on Monday?
I expect forward guidance to be revised based on likely progress with China Resources with a conservative caveat implying that this is dependent on completion of the deal.
I can’t see why the CEO would tweet about the chambers of commerce if Gerard and Linian LI were not confident of progress towards the 30th June implied target date.
I have no doubt that the recent placing has strengthened what is a predominately private shareholder register. Management and new institutions in the recent placing will be invested over a longer time frame.
Volume is by no means significant which in turn reduces liquidity and increases volatility. It will be newsflow that ultimately drives this share price.
Take advantage of the dips if you believe in the fundamentals. It may of taken some time to hit the commercial end of the newsflow that will reinvigorate interest, but I see no reason to disbelieve the imminent timetable.
Sorry, this was meant for DVRG. But this will have a direct bearing on this stock and they should both move in tandem
- 23rd June
General meeting results
- 28th June
Audited results and ‘forward guidance’.
- 30th June (imminent)
Mou update, signature and commercial guidance
- Imminent (as per comms from company)
Breath test
With additional information coming for all quarters of the business model during Q3, what drives the share price? Newsflow!
We are at the commercial end of proceedings, this is now Deepverge’s moment, and the market and its respective investors are not only fully aware of what is forthcoming, but that new shares are to be issued to those that committed with this in mind. Any affect on share price. I doubt it!
Imminent rerating and pick up in volume will keep us all on our toes! Enjoy!